SPONSOR
MediLink Therapeutics (Suzhou) Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 1, Phase 2, Phase 3, Phase 1
Conditions studied: Metastatic Castration-resistant Prostate Cancer (mCRPC)Recurrent or Metastatic Nasopharyngeal CarcinomaNSCLCBreast CancerHNSCCLocally Advanced or Metastatic Solid TumorsAdvanced Esophageal Squamous Cell CarcinomaAdvanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd. is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Metastatic Castration-resistant Prostate Cancer (mCRPC), Recurrent or Metastatic Nasopharyngeal Carcinoma, NSCLC, Breast Cancer.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — MediLink Therapeutics (Suzhou) Co., Ltd.
How many clinical trials has MediLink Therapeutics (Suzhou) Co., Ltd. sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by MediLink Therapeutics (Suzhou) Co., Ltd., of which 5 are actively recruiting participants. These trials cover conditions including Metastatic Castration-resistant Prostate Cancer (mCRPC), Recurrent or Metastatic Nasopharyngeal Carcinoma, NSCLC. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does MediLink Therapeutics (Suzhou) Co., Ltd. research focus on?
MediLink Therapeutics (Suzhou) Co., Ltd. clinical trials span Metastatic Castration-resistant Prostate Cancer (mCRPC), Recurrent or Metastatic Nasopharyngeal Carcinoma, NSCLC, Breast Cancer, HNSCC, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a MediLink Therapeutics (Suzhou) Co., Ltd. clinical trial?
To participate in a MediLink Therapeutics (Suzhou) Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all MediLink Therapeutics (Suzhou) Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06241846 Phase 2
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07258979 Phase 1, Phase 2
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06107686 Phase 2
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NSCLC
NCT07487896 Phase 3
Recruiting
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Advanced Esophageal Squamous Cell Carcinoma
NCT06859762 Phase 1
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology